Tags

Type your tag names separated by a space and hit enter

Treatment options for the management of pervasive developmental disorders.
Int J Psychiatry Med. 2016; 51(2):201-10.IJ

Abstract

Autism spectrum disorder (previously known as pervasive developmental disorders) is characterized by social communication deficits, impaired functioning, and restrictive or repetitive behaviors and interests. Patients with autism spectrum disorder also commonly experience core maladaptive behaviors such as aggression and irritability, self-injurious behaviors, hyperactivity, and sleep abnormalities. These behaviors may be sources of stress for caregivers and patients alike and may require pharmacologic management. Risperidone and aripiprazole are frequently used to treat both irritability and self-injurious behavior related to autism spectrum disorder. The opioid antagonist naltrexone has also been studied for self-injurious behaviors, although long-term data are lacking when used in the autism spectrum disorder population. Methylphenidate, atomoxetine, clonidine, and guanfacine are all potential options for the treatment of hyperactivity or attention-deficient hyperactivity disorder-like symptoms in patients with autism spectrum disorder. Lastly, melatonin is the most widely researched medication strategy for the management of sleep disorders in autism spectrum disorder. Future studies reviewing new pharmacologic treatment approaches in combination with non-pharmacologic therapies are warranted to ensure that target behaviors of autism spectrum disorder are appropriately managed.

Authors+Show Affiliations

Department of Clinical Pharmacy Services, Greenville Health System, Greenville, SC, USA knash@ghs.org.Department of Clinical Pharmacy Services, Greenville Health System, Greenville, SC, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27079778

Citation

Nash, Kathryn, and K Jennifer Carter. "Treatment Options for the Management of Pervasive Developmental Disorders." International Journal of Psychiatry in Medicine, vol. 51, no. 2, 2016, pp. 201-10.
Nash K, Carter KJ. Treatment options for the management of pervasive developmental disorders. Int J Psychiatry Med. 2016;51(2):201-10.
Nash, K., & Carter, K. J. (2016). Treatment options for the management of pervasive developmental disorders. International Journal of Psychiatry in Medicine, 51(2), 201-10. https://doi.org/10.1177/0091217416636600
Nash K, Carter KJ. Treatment Options for the Management of Pervasive Developmental Disorders. Int J Psychiatry Med. 2016;51(2):201-10. PubMed PMID: 27079778.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment options for the management of pervasive developmental disorders. AU - Nash,Kathryn, AU - Carter,K Jennifer, PY - 2016/4/16/entrez PY - 2016/4/16/pubmed PY - 2017/7/1/medline KW - autism spectrum disorders KW - pervasive developmental disorders SP - 201 EP - 10 JF - International journal of psychiatry in medicine JO - Int J Psychiatry Med VL - 51 IS - 2 N2 - Autism spectrum disorder (previously known as pervasive developmental disorders) is characterized by social communication deficits, impaired functioning, and restrictive or repetitive behaviors and interests. Patients with autism spectrum disorder also commonly experience core maladaptive behaviors such as aggression and irritability, self-injurious behaviors, hyperactivity, and sleep abnormalities. These behaviors may be sources of stress for caregivers and patients alike and may require pharmacologic management. Risperidone and aripiprazole are frequently used to treat both irritability and self-injurious behavior related to autism spectrum disorder. The opioid antagonist naltrexone has also been studied for self-injurious behaviors, although long-term data are lacking when used in the autism spectrum disorder population. Methylphenidate, atomoxetine, clonidine, and guanfacine are all potential options for the treatment of hyperactivity or attention-deficient hyperactivity disorder-like symptoms in patients with autism spectrum disorder. Lastly, melatonin is the most widely researched medication strategy for the management of sleep disorders in autism spectrum disorder. Future studies reviewing new pharmacologic treatment approaches in combination with non-pharmacologic therapies are warranted to ensure that target behaviors of autism spectrum disorder are appropriately managed. SN - 0091-2174 UR - https://www.unboundmedicine.com/medline/citation/27079778/Treatment_options_for_the_management_of_pervasive_developmental_disorders_ L2 - http://journals.sagepub.com/doi/full/10.1177/0091217416636600?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.